If your pharmacist just told you Ozempic "isn't on your formulary," that's a different problem than a prior authorization delay — and it needs a different fix. A formulary exception is the specific mechanism for asking your plan to cover a drug it has chosen not to include on its covered-drug list at all.
This happens to Ozempic more than people expect. Pharmacy benefit managers rebuild their preferred drug lists every January, and GLP-1 medications are some of the most frequently reshuffled products on those lists because of their cost and the competing rebate deals manufacturers offer. A plan that covered Ozempic in 2025 can exclude it in 2026 in favor of Mounjaro, Trulicity, or Rybelsus — even for patients who've been stable on Ozempic for years.
This guide walks through what a formulary exception actually changes, how it's different from the prior authorization and step therapy processes people often confuse it with, what your prescriber needs to submit, and what happens if the request is denied.
What an Ozempic Formulary Exception Actually Is
Every insurance plan and Medicare Part D plan maintains a formulary — a list of drugs it agrees to cover, organized into cost-sharing tiers. When a drug isn't on that list, the plan treats it as excluded: if you fill it anyway, you generally pay the full cash price, and nothing counts toward your deductible or out-of-pocket maximum.
A formulary exception asks the plan to make a one-time or plan-year exception to that rule for a specific patient. Your prescriber submits a supporting statement arguing that the formulary alternatives — the drugs the plan does cover for the same condition — aren't appropriate for you, and that Ozempic is medically necessary instead.
| Feature | Detail |
|---|---|
| Who requests it | Your prescriber submits the clinical statement; you can start the process by confirming Ozempic's formulary status with your plan |
| When it applies | Only when Ozempic is not on your plan's formulary at all — not when it's covered but restricted |
| What the plan reviews | Whether covered alternatives would be ineffective, cause adverse effects, or are otherwise not appropriate for you specifically |
| If approved | Ozempic is covered at a cost-sharing level the plan sets — typically the plan's non-preferred or specialty tier, not automatically the lowest tier |
| Duration | Commonly through the end of the current plan year for Medicare Part D; commercial plan durations vary |
Why this matters: An approved formulary exception is not the same as Ozempic moving onto the formulary permanently. It's an individual accommodation tied to your specific request — if you switch plans or the plan year resets, you may need to request it again.
Formulary Exception vs. Prior Authorization vs. Tiering Exception
These three terms get used interchangeably, but they solve different problems and go through different review criteria. Getting the label wrong is one of the most common reasons an Ozempic request stalls — the paperwork ends up on the wrong desk.
| Term | What It Means | When It Applies to Ozempic |
|---|---|---|
| Prior Authorization | Your prescriber must get approval before a covered drug is dispensed | Applies on most plans even when Ozempic is on the formulary for type 2 diabetes |
| Formulary Exception | Requests coverage for a drug that isn't on the formulary at all | Applies when your plan excluded Ozempic outright in favor of a preferred alternative |
| Tiering Exception | Requests a lower copay for a drug that's on the formulary but on an expensive tier | Applies when Ozempic is covered but placed on a high-cost specialty tier |
| Step Therapy Exception | Requests to skip a required "try this first" medication | Applies when the plan requires trying metformin or another agent before approving Ozempic |
Not sure which one applies to you? If your pharmacy or insurance portal specifically uses the words "non-formulary," "not covered," or "excluded drug," you need a formulary exception. If it says "prior authorization required" or "requires approval," Ozempic is already covered and you need our Ozempic prior authorization guide instead.
Why Ozempic Specifically Ends Up Needing One
Ozempic (semaglutide) is FDA-approved for type 2 diabetes — to improve blood sugar control, and to reduce cardiovascular risk in adults with type 2 diabetes and known heart disease. It is not FDA-approved for weight loss; Wegovy, a higher-dose formulation of the same active ingredient, holds that approval instead. That distinction shapes almost every coverage decision involving Ozempic.
Beyond the indication issue, Ozempic's formulary status is genuinely unstable from one plan year to the next. The three largest pharmacy benefit managers — CVS Caremark, Express Scripts, and Optum Rx — each publish their own annual exclusion lists, and GLP-1 medications are frequently reshuffled based on manufacturer rebate negotiations rather than clinical differences between the drugs.
- Your plan may prefer a different GLP-1 for diabetes. A plan can exclude Ozempic and designate Mounjaro, Trulicity, or Rybelsus as its preferred option for type 2 diabetes instead.
- Formularies change every January 1. Coverage that applied last year isn't guaranteed to carry over — always re-verify status at the start of a new plan year, especially if you're due for a refill in January.
- Weight-loss GLP-1s are treated separately from diabetes GLP-1s. Many plans that cover Ozempic for diabetes still exclude Wegovy, Zepbound, or Saxenda for weight loss — these are evaluated under different formulary rules entirely.
Why this matters: If your plan already covers Ozempic for type 2 diabetes but wants approval first, you don't need a formulary exception — a clean prior authorization submission will resolve it faster. Save the formulary exception process for when Ozempic has actually been excluded from your plan's covered-drug list.
What's Actually Happening at Your Pharmacy?
What did the rejection message actually say?
Check the exact wording on your pharmacy receipt or plan portal
This is a formulary exception
Ozempic isn't on your plan's drug list at all
Prescriber submits supporting statement
Decision in 72 hrs standard, 24 hrs if urgent (Medicare Part D)
This is a different process
Ozempic is covered; the plan wants clinical justification first
Use the PA or step-therapy path
See our Ozempic prior authorization guide instead
Denied?
You can appeal internally, then request independent external review
Rules and Timelines by Plan Type
Formulary exception rules aren't uniform across every kind of insurance. Medicare Part D operates under specific federal regulations; commercial plans follow a mix of internal policy, ERISA claims rules, and — for fully-insured plans — state insurance law.
| Plan Type | Governed By | Standard Decision | Expedited Decision |
|---|---|---|---|
| Medicare Part D | CMS Part D coverage determination rules | 72 hours* | 24 hours* |
| Commercial, fully insured | State insurance law and, in many states, formulary/step-therapy reform statutes | Often 72 hours, but varies by state | Often 24 hours, but varies by state |
| Commercial, self-funded (ERISA) | ERISA claims procedure regulation (29 CFR §2560.503-1); state law generally does not apply | Set by the plan's summary plan description | 72 hours for urgent care claims |
| Medicaid managed care | State Medicaid contract | Varies by state | Varies by state |
*Timeframes begin once the plan receives your prescriber's supporting statement, not from the date you first ask about the exception.
Self-funded employer plans are the exception to the exception. Around 61% of Americans with employer coverage are in self-funded plans regulated by ERISA, which generally preempts state formulary-exception laws. If your plan is self-funded, ask HR or the plan's summary plan description for its specific exception timeline rather than assuming a state-mandated deadline applies.
How to Request an Ozempic Formulary Exception
Confirm it's actually a formulary exclusion
Log in to your plan's member portal or call the number on your insurance card and ask specifically whether Ozempic is "on formulary" for your plan, or whether the rejection was for prior authorization, step therapy, or a quantity limit instead.
Ask for the exception request form
Most plans and PBMs have a specific coverage determination or formulary exception form, separate from the standard prior authorization form. Using the correct form avoids the request being misrouted.
Your prescriber writes the supporting statement
This needs to explain your diagnosis, why the plan's covered alternatives (for example, a preferred GLP-1 the plan does cover) aren't appropriate for you — due to prior ineffectiveness, an adverse reaction, or a contraindication — and why Ozempic specifically is medically necessary.
Submit through the plan's official channel
This is usually fax, an online provider portal, or mail, depending on the plan. Confirm the correct submission address or portal before sending — a request sent to a general customer service line can sit unprocessed.
Track the clock
The decision timeframe starts when the plan receives your prescriber's statement, not your initial phone call. Ask your prescriber's office to confirm the fax or portal submission was received.
Get the decision in writing
An approval letter should state the cost-sharing tier that applies and how long the approval lasts. A denial letter must explain the specific reason and how to appeal.
Documentation Your Prescriber Will Need
| Item | Why the Plan Needs It |
|---|---|
| Type 2 diabetes diagnosis (ICD-10 code) and relevant labs (A1C) | Confirms the request matches an FDA-approved indication for Ozempic |
| History with formulary alternatives, if any | Shows whether a covered GLP-1 was already tried and was ineffective or not tolerated |
| Documented contraindications or adverse reactions | Explains specifically why the plan's preferred alternative isn't appropriate for you |
| Current medication list | Identifies potential interactions the reviewer needs to consider |
| Insurance ID, group number, and plan year | Confirms which formulary and exception rules apply to your specific plan |
Medicare, Weight Loss, and the GLP-1 Bridge
This is the area where formulary exceptions for Ozempic get misunderstood most often, so it's worth being direct: a formulary exception cannot make Medicare Part D cover Ozempic for weight loss. Federal law has excluded weight-management drugs from Medicare Part D coverage since 2003, and that statutory exclusion sits above the exception process — no amount of medical necessity documentation can override it for an off-label use.
Ozempic itself is only FDA-approved for type 2 diabetes and cardiovascular risk reduction in that population, so Medicare Part D can cover it through the ordinary formulary or exception process for those indications, subject to your plan's rules and prior authorization requirements.
If your goal is weight loss under Medicare, Ozempic isn't the mechanism. A separate, temporary CMS demonstration called the Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027, covering Wegovy and Zepbound — not Ozempic — for eligible Part D enrollees at a $50 monthly copayment. Eligibility is based on a BMI of 35 or higher alone, or 27 or higher with qualifying comorbidities. Coverage depends on participation by your specific Part D plan and drug manufacturer, so it isn't guaranteed for every enrollee.
A related, larger initiative called the BALANCE Model was originally planned to expand Medicare Part D weight-loss coverage starting January 2027, alongside a Medicaid rollout beginning as early as May 2026. As of this writing, CMS has indefinitely delayed the Part D portion of BALANCE and extended the GLP-1 Bridge demonstration through the end of 2027 instead. Because these programs are actively evolving, confirm current status directly through CMS's Medicare GLP-1 Bridge page or your Part D plan before assuming a specific rule applies.
There's also a separate, unrelated development worth knowing about: Ozempic (along with Rybelsus and Wegovy, since they share the same active ingredient) was selected for the second round of Medicare drug price negotiation under the Inflation Reduction Act. The negotiated price — about $274 for a 30-day supply, down from a list price near $959 — takes effect January 1, 2027, not in 2026. This negotiated price applies to what Medicare pays; it doesn't change formulary placement or exception rules on its own.
For the full Part D coverage picture — how Medicare drug plans work, what formulary tiers mean, and how the exception process fits into the broader Part D appeals system — see our Medicare Part D coverage guide and Medicare formulary exception guide.
What Ozempic Costs, With and Without an Exception
An approved formulary exception typically doesn't mean the lowest possible copay — it means the plan agrees to apply some coverage tier to the drug, usually its non-preferred or specialty tier, rather than 100% cash price.
| Scenario | Typical Monthly Cost |
|---|---|
| Cash price, no insurance or exception | Roughly $935–$1,000+, varying by pharmacy |
| Commercially insured, Ozempic on formulary for diabetes | Plan's standard copay or coinsurance, commonly in the $25–$150+ range depending on tier |
| Commercially insured + NovoCare Savings Card (plan covers Ozempic) | As little as $25, subject to monthly savings caps and a 48-month program limit |
| Formulary exception approved (commercial) | Plan's non-preferred or specialty-tier cost share — check your approval letter for the exact amount |
| Medicare Part D, exception approved | Cost-share set by the plan's exception decision; the NovoCare savings card cannot be used with Medicare |
| Uninsured, income at or below 200% of Federal Poverty Level | Potentially $0 through the Novo Nordisk Patient Assistance Program, subject to current eligibility rules |
| Uninsured, self-pay through NovoCare Pharmacy | Roughly $349–$499 depending on dose; confirm current pricing, as manufacturer self-pay rates change |
The manufacturer savings card has limits tied to formulary status. The standard Ozempic savings card is built for commercially insured patients whose plan already provides some coverage for Ozempic. Novo Nordisk's own terms note the offer can be reduced or discontinued if your insurance no longer covers the drug — so if your formulary exception is denied, don't assume the $25 card still applies at full value. It's never usable with Medicare, Medicaid, TRICARE, VA, or other government coverage. See our Ozempic savings card guide and Ozempic cost without insurance guide for the full breakdown.
If Your Exception Is Denied: How to Appeal
A denial is a starting point for an appeal, not a final answer. The path differs depending on whether you have Medicare Part D or commercial coverage.
| Plan Type | Next Step | Typical Timeline |
|---|---|---|
| Medicare Part D | Request a Level 1 redetermination from your plan | 7 days standard, 72 hours expedited |
| Medicare Part D | If upheld, escalate to the independent review entity (Level 2) | Timeline stated in your redetermination denial notice |
| Medicare Part D | Administrative Law Judge hearing (Level 3) | Requires an amount in controversy of roughly $190 in 2026 |
| Commercial (ACA-regulated) | Internal appeal, then independent external review by an accredited IRO | External review: 45 days standard, 72 hours expedited; must be requested within about 4 months of the final internal denial |
Read the denial letter closely
It must state the specific reason for denial and the exact deadline and process for appealing — this determines which document your prescriber needs to address point by point.
File the internal appeal with new or clarified documentation
Most denials are overturned because the second submission directly answers the plan's stated reason, rather than simply resubmitting the same paperwork.
Escalate to external review if the internal appeal fails
For ACA-regulated commercial plans, an independent, accredited Independent Review Organization makes the final call, and its decision is binding on the insurer — the plan cannot simply overrule it.
Common Mistakes That Slow Down Approval
- Submitting a standard prior authorization form when the drug is actually non-formulary, which routes the request to the wrong review team.
- Assuming last year's approved exception automatically carries over into a new plan year.
- Leaving out documentation of why a specific covered alternative isn't appropriate — a vague statement of preference is not the same as documented medical necessity.
- Confusing the manufacturer savings card with insurance coverage — the card reduces a copay, it doesn't create coverage where none exists.
- Assuming a formulary exception can secure Medicare coverage for weight-loss use, which the exception process cannot do.
- Missing the appeal deadline because the denial letter's timeline wasn't reviewed carefully.
Real Examples: How This Plays Out
Example 1 — Commercial plan, PBM exclusion: A patient with type 2 diabetes has used Ozempic successfully for two years. On January 1, their employer's plan switches PBMs, and the new formulary excludes Ozempic in favor of Trulicity. Their endocrinologist submits a formulary exception documenting that the patient previously had inadequate glycemic control on a different GLP-1 and has been stable on Ozempic since — the plan approves coverage at its specialty tier.
Example 2 — Medicare Part D, diabetes indication: A Medicare beneficiary's Part D plan doesn't include Ozempic on its formulary. Their prescriber submits a formulary exception request with A1C history and documentation that metformin alone wasn't sufficient. Under the federal 72-hour standard timeline, the plan approves the exception at its non-preferred drug tier.
Example 3 — Weight-loss request denied, redirected to the Bridge program: A Medicare beneficiary without diabetes asks their doctor to request a formulary exception for Ozempic to support weight loss. The plan denies it, correctly citing the statutory exclusion on weight-loss drugs. Their doctor instead evaluates them for the Medicare GLP-1 Bridge program, which covers Wegovy or Zepbound — not Ozempic — for eligible enrollees based on BMI and comorbidity criteria.
Formulary Exception vs. Income-Based Assistance
A formulary exception changes what your existing insurance will pay for. It has nothing to do with your income, and it doesn't help if you're uninsured. If cost — not coverage — is the real obstacle, that's a separate set of programs.
| Program | What It Solves | Income-Based? |
|---|---|---|
| Ozempic formulary exception | Gets your existing plan to cover a drug it currently excludes | No |
| NovoCare Savings Card | Reduces the copay for commercially insured patients whose plan already covers Ozempic | No |
| Novo Nordisk Patient Assistance Program | Potential free medication for uninsured patients at or below 200% of the Federal Poverty Level | Yes |
| NovoCare Pharmacy self-pay pricing | A fixed cash price for uninsured patients who don't qualify for the assistance program | No |
If cost, rather than approval, is your real barrier, our Ozempic Patient Assistance Program guide and Ozempic cost without insurance guide cover the income-based options in detail. If you already have an approved exception but want to manage refills more predictably, our Ozempic mail-order guide covers 90-day supply options.
Bottom Line
A formulary exception is the right tool only when Ozempic has been excluded from your plan's covered-drug list entirely — not when it's covered but requires prior authorization or step therapy first. Getting that distinction right, and having your prescriber document specifically why formulary alternatives aren't appropriate for you, is what actually moves these requests through on the first submission.
For Medicare beneficiaries, remember that the exception process works for Ozempic's approved diabetes indication, but it can't be used to secure Part D coverage for weight loss — that's governed by separate, evolving federal demonstration programs. If you're denied, you have real appeal rights at every level; don't let a deadline pass without acting.